Case reports
Case I A 45-year old woman presented with stage IV centroblastic-centrocytic follicular lymphoma. Treatment with fludarabine at a dose of 25 mg m2 daily for 5 days at intervals of 4 weeks was given following unsatisfactory responses to chlorambucil and cyclophosphamide/doxorubicin/vincristine prednisolone (CHOP).
The first cycle of fludarabine treatment was complicated by the sudden onset of severe generalised headache 2 h after the first dose. There were no neurological signs on examination and a computerised tomographic (CT) scan of the brain with contrast enhancement was normal, as was examination of the cerebrospinal fluid (CSF). Fludarabine was continued, during which time the headaches persisted, finally resolving 2 weeks after the start of treatment. A similar headache of lesser intensity occurred on the third day of chemotherapy in the second cycle and persisted for 1 week.
The third cycle of chemotherapy was associated with only mild headache, but on the tenth day from the start of treatment the patient noticed recurrent numbness in the right hand, subsequently spreading to involve the right arm, face and leg. On examination she had a right-sided hemiparesis, normal. CT scanning and examination of the CSF were not performed. No further treatment with fludarabine was given. One year later the patient developed high-grade T-cell lymphoma in the bone marrow, for which she was treated with combination chemotherapy followed by high-dose cyclophosphamide and total body irradiation with peripheral blood progenitor cell rescue. She remains in complete remission and has had no further episodes of neurological disturbance.
Case 3
A 52-year-old man had been treated 9 years previously for centroblastic-centrocytic follicular lymphoma. Second remission was consolidated with high-dose cyclophosphamide and total body irradiation with autologous bone marrow rescue.
Asymptomatic bone marrow recurrence was diagnosed 3 years after the myeloablative treatment.
Two years later the patient developed arthralgia, mouth Four years after detection of the recurrence of lymphoma in the bone marrow the patient developed peripheral lymphadenopathy and became neutropenic and thrombocytopenic. This was not improved by cessation of azathioprine treatment or by adminstration of prednisolone and chlorambucil. Treatment with fludarabine 25 mg m-2 daily for 5 days was commenced while the patient continued taking prednisolone 40 mg daily. On the 19th day of the second cycle the patient developed paraesthesie and weakness on the left side, identical to his symptoms at the time of his previous cerebrovascular accdent. He attended hospital 5 days later, by which time the symptoms had resolved, and on examination no new neurological signs could be elicited. A contrastenhanced CT scan of the brain was normal. The blood count showed marked improvement and a third cycle of treatment was therefore given 1 week later. On day 25 the left-sided weakness and paraesthesiae recurred, only to resolve 3 days later.
Case 4
A 68-year-old man presented with a stage IV low-grade T-ell lymphoma of Lennert's type. He was treated with fludarabine 25 mg m2 daily for 5 days at 4 week intervals with a satisfactory response after the first cycle. Twelve days from the start of the second cycle the patient noticed heaviness of the hands and feet, with marked limb weakness. On examination he showed global loss of power in the limbs and areflexia. Bulbar function and sensation were unaffected.
A contrast-enhanced CT scan of the brain was normal, but excamination of the CSF showed an elevated protein level at 0.93 g 1'. No oligoclonal bands were detectable. Cytology of the CSF was normal and microbiology negative. Nerve conduction studies showed abnormal small sensory action potentials and only marginally reduced motor conduction velocity.
The patient's symptoms gradually worsened with progressive weakness and breathlssness. Treatment with intravenous immunoglobulin 0.6 g kg-' on three consecutive days was without effect, and repeat nerve conduction studies 2 weeks after the first showed clear deterioration with findings suggestive of a patchy diffuse demyelinating neuropathy. The vital capacity, however, remained above 21, bulbar function was intact and a 24 h ECG recording showed no significant dysrhythmias. The weakness showed gradual spontaneous improvement from 6 weeks after the last dose of chemotherapy and had resolved completely 4 months later.
Computerised tomographic scans showed almost complete resolution of the previous lymphadenopathy, and a bone marrow biopsy showed no evidence of lymphoma. The patient was observed without further therapy and remains well 12 months from the start of treatment.
Case 5
A 59-year-old man with chronic lymphatic leukaemia had been observed without requiring treatment for 3 years from the time of diagnosis on a routine blood count. When he developed increasing lymphadenopathy and anaemia chlorambucil was given with only minimal response. Further treatment with fludarabine 25 mg m2 daily for 5 days was therefore given, but on the 12th day from the start of this he developed breathlessness and a dry cough with a chest radiograph showing bilateral perihilar interstitial infiltrates consistent with Pnewnocystis carinii pneumonia. He was treated with high-dose co-trimoxazole and his condition steadily improved. He was also given vitamin B12 and folic acid supplements in view of the depression of erythropoiesis.
On the 16th day after the first dose of fludarabine he developed a marked tremor with unsteadiness of gait. On examination he had a postural tremor, global weakness of all four limbs, areflexia and impaired joint position sense. A contrast-enhanced CT scan of the brain was normal, as was examination of the CSF. Nerve conduction studies showed marked slowing of motor conduction velocities in the lower limb without any abnormality of compound muscle action potentials. The sensory action potential amplitudes were normal. The findings were suggestive of a predominantly motor demyelinating peripheral neuropathy. He made an uneventful recovery with conservative management and the neurological signs resolved after I month. He was subsequently observed without active treatment for the leukaemia once again, and treated with cyclosporin A for red cell aplasia. He remains well I year later.
Dbcsion
Fludarabine given at a dose of 25 mg m-2 as an intravenous bolus for five consecutive days is generally very well tolerated. Although myelosuppression can occasionally be severe and infectious compLications occur, in general the treatment is of low toxicity. One hundred and forty patients have received fludarabine at St Bartholomew's Hospital in the last 3 years, so that five cases reflect an uncommon problem.
There are few previous reports of neurotoxicity associated with the use of fludarabine at these doses. One study reported reversible grade III toxicity with visual and auditory changes in up to 10% of subjects (Hochster et al., 1992) and one report described severe symptoms developing in a patient with cerebral lymphoma (Merkel et al., 1986) . There are two case reports of reversible motor deficits and white matter abnormalities on MRI scans which bear some resemblance to cases 1, 2 and 3 in this account (Cohen et al., 1993) , and the reports of peripheral neuropathy seen in patients treated with the combination of fludarabine and cytosine arabinoside show considerable similarity to cases 4 and 5 (Kornblau et al., 1993) .
It is not certain that these events were directly attributable to treatment with fludarabine: patients with lymphoma are subject to a variety of neurological complications (Henson & Urich, 1982) , and peripheral demyelination is among those commonly seen. It would be difficult to postulate a common mechanism by which these vanous syndromes might have arisen. However, the temporal relationship to the administration of fludarabine is striking, particularly in cases 1 and 2, in whom the headaches arose during the week of treatment, and case 3, in whom the symptoms of a previous cerebrovascular event appred to be recalled by each cycle of treatment, without other findings to suggest recurrent infarction. It is possible that the demyelinating neuropathy of case 4 was coincidental or related to the lymphoma, although this was regresing at the time the neuropathy developed. It could also be argued that in case 5 the neuropathy arose as a complication of the chest infection, but this seems less likely as the delay between the two events was only 4 days.
The histological findings at autopsy in case 1 were highly unusual, with vascular intimal hyperplasia suggestive of moya-moya' disease (Suzuki & Takaku, 1969) , although the angiographic appearances were not typical. While this also might be related to the malignancy, there are no previous similar cases, and the absence of any cerebral lymphoma at post-mortem makes it unlikely. The development of severe headaches is an unusual side-effect of treatment with fludarabine (or indeed any chemotherapy), but it seems quite probable that they were related to the onset of the injury. These cases suggest that caution should be exercised in the administration of fludarabine at conventional doses, and adverse neurological events carefully characterised and reported. Patients with pre-existing neurological deficits could be subject to deterioration of their condition although this may well prove reversible. The onset of severe headache should be a cause for concern in the light of this report, and consideration given to stopping treatment. Full neurological assessment must be carried out promptly in all cases, including detailed imaging of the brain, examination of the CSF and where indicated vascular and electrophysiological studies.
